Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin

Moura, Alexandre Sampaio; Carmo, Ricardo Andrade; Teixeira, Antônio Lúcio; Teixeira, Mauro Martins; Rocha, Manoel Otávio da Costa

doi:10.1590/s0074-02762011000100006

Cited by 11 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these studies have shown that cytokines could be used as predictors of treatment outcome [17]. …”

Section: Discussionmentioning

confidence: 99%

“…Moreover, control of HCV infection may depend in part on chemokine-mediated recruitment of specific T cells to the liver [19]. In this context, Moura et al, [17] evaluated the association between pretreatment plasma levels of chemokines CCL2, CCL3, CCL11, CCL24, CXCL9, CXCL10 and soluble tumor necrosis factor receptors and the virological response in CHC-treated patients. They found that pretreatment CXCL10 level predicts EVR and SVR to IFN-α and ribavirin and may therefore be useful in the evaluation of candidates for therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Zekri

Bahnassy

Mohamed

et al. 2013

Virol J

View full text Add to dashboard Cite

BackgroundCombined pegylated interferon-α and ribavirin therapy has sustained virological response (SVR) rates of 54% to 61%. Pretreatment predictors of SVR to interferon therapy have not been fully investigated yet. The current study assesses a group of chemokines that may predict treatment response in Egyptian patients with chronic HCV infection.Patients and methodsCXCL5, CXCL9, CXCL11, CXCL12, CXCL 13, CXCL 16 chemokines and E-Cadherin were assayed in 57 chronic HCV patients’ sera using quantitative ELISA plate method. All studied patients were scheduled for combined pegylated interferon alpha and ribavirin therapy (32 patients received pegylated interferon α 2b, and 25 patients received pegylated interferon α 2a). Quantitative hepatitis C virus RNA was done by real time RT-PCR and HCV genotyping by INNOLIPAII.ResultsThere was no significant difference (p > 0.05) in baseline HCV RNA levels between responders and non-responders to interferon. A statistically significant difference in CXCL13 (p = 0.017) and E-Cadherin levels (P = 0.041) was reported between responders and nonresponders at week 12. Significant correlations were found between changes in the CXCL13 levels and CXCL9, CXCL16, E-cadherin levels as well as between changes in E-cadherin levels and both CXCL16 and ALT levels that were maintained during follow up. Also, significant changes have been found in the serum levels of CXCL5, CXCL13, and CXCL16 with time (before pegylated interferon α 2 a and α 2 b therapy, and at weeks 12 and 24) with no significant difference in relation to interferon type and response to treatment.ConclusionSerum levels of CXCL13 and E-Cadherin could be used as surrogate markers to predict response of combined PEG IFN-α/RBV therapy, especially at week 12. However, an extended study including larger number of patients is needed for validation of these findings.Clinical trial NoNCT01758939

show abstract

“…Some of these studies have shown that cytokines could be used as predictors of treatment outcome [17]. …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Zekri

Bahnassy

Mohamed

et al. 2013

Virol J

View full text Add to dashboard Cite

show abstract

“…TNF-α receptors are actually membrane receptors that have been separated from activated neutrophils, mononuclear blood cells and fibroblasts and became soluble receptors that are able to bind circulating TNF-α and are important in regulating its activity [19]. Therefore, sTNF-α receptor levels may serve as a sensitive monitoring of the activity of the TNF-α system [19,38].…”

Section: Discussionmentioning

confidence: 99%

Zinc Oxide Nanoparticles: The Hidden Danger

Shemy¹

2017

IJBBMB

View full text Add to dashboard Cite

Abstract:Zinc oxide nanoparticles (ZnO-NPs) are used in many industries and medications, increasing the exposure to ZnO-NPs that may have harmful side effects. So, we studied the hepatotoxic effect of ZnO-NPs and explored the role of vitamin E in the reduction of their toxic effects. Forty male albino rats, divided into four groups (10 rats per group) were included in the study; control group, ZnO-NPs intoxicated group, vitamin E control group and vitamin E protected ZnO-NPs intoxicated group. ZnO-NPs were given in a dose of 400 mg / kg body weight for seven days. Vitamin E was given in a dose of 100 mg / kg body weight for four weeks. Our results showed that ZnO-NPs induced liver damage indicated by significant increase of serum ALT and AST and significant decrease of serum albumin and total protein levels. Moreover, ZnO-NPs induced oxidative stress in the liver suggested by significant elevation of malondialdehyde level and significant reduction of reduced glutathione level, glutathione peroxidase activity and glutathione peroxidase-1 expression in liver homogenate. Furthermore, ZnO-NPs caused significant increase in the serum pro-inflammatory biomarker, tumor necrosis factor alpha (TNF-α). On the other hand, vitamin E alleviated the liver damage, oxidative stress and the elevated serum TNF-α induced by ZnO-NPs.

show abstract

“…In a broad screening study of baseline CCL and CXCL chemokines, only CXCL10 was significantly associated to lack of SVR (Moura et al, 2011). In another study high CXCL10 gene expression during treatment (Sixtos-Alonso et (Moura et al, 2011) were negative predictors of SVR. Finally, in two other studies baseline levels of IP10 were associated with a negative prognostic response to treatment with peg-IFN-and ribavirin (Butera et al, 2005;Lagging et al, 2006).…”

Section: Chemokines At Baselinementioning

confidence: 96%

“…the higher IL-8 levels, the lower chance of SVR (Akbar et al, 2011). In a broad screening study of baseline CCL and CXCL chemokines, only CXCL10 was significantly associated to lack of SVR (Moura et al, 2011). In another study high CXCL10 gene expression during treatment (Sixtos-Alonso et (Moura et al, 2011) were negative predictors of SVR.…”

Section: Chemokines At Baselinementioning

confidence: 97%

Chemokine Responses to Hepatitis C Virus and Their Impact in Mediating the Treatment Responses of Antiviral Treatment

Florholmen¹,

Goll²

2012

Insight and Control of Infectious Disease in Global Scenario

View full text Add to dashboard Cite

Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin

Cited by 11 publications

References 49 publications

Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Zinc Oxide Nanoparticles: The Hidden Danger

Chemokine Responses to Hepatitis C Virus and Their Impact in Mediating the Treatment Responses of Antiviral Treatment

Contact Info

Product

Resources

About